Biopharmaceutical services provider Parexel has introduced a new offering, one that will see the team deliver an end-to-end offering that provides a wide variety of communication services throughout the drug development and commercialisation process.
The medical writing solutions team is made up of more than 800 employees globally and will develop ‘high-quality’ documents, such as protocols, new drug applications, medical education materials and regulatory authority meeting documents.
Julia Cooper, vice president, head of global medical writing solutions at Parexel, said: “As the drug development journey continues to evolve with the advancements in trial design and technology, and regulatory requirements change, it is vital that clients have access to highly-experienced medical writers who can communicate with all stakeholders in an integrated way, eliminating silos and telling a more holistic story through each stage of development and commercialisation.
“Our deep cross-functional expertise enables us to optimise the medical writing process for our clients, and ultimately allows them to engage more effectively with audiences that are critical in bringing new therapies to market.”
Parexel’s new offering is available as both functional service projects or as part of larger strategic partnerships.